An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
This is an open-label, multicenter, non-randomized extension study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and do not have access to the study treatment locally, continue to receive study treatment in this extension study.
Neoplasms
DRUG: Atezolizumab|DRUG: Bevacizumab|DRUG: Pemetrexed|DRUG: Paclitaxel|DRUG: Enzalutamide
Number of Participants With Continued Access to Atezolizumab-based Therapy and/or Comparator Agent(s), Up to approximately 4 years
Percentage of Participants With Serious Adverse Events (SAEs), Up to 90 days after the final dose of study treatment (up to approximately 4 years)|Percentage of Participants With Adverse Events of Special Interest (AESIs), Up to 90 days after the final dose of study treatment (up to approximately 4 years)
This is an open-label, multicenter, non-randomized extension study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and do not have access to the study treatment locally, continue to receive study treatment in this extension study.